NEWS RELEASE

Teijin Pharma Receives Additional Approval in Japan for
Abaloparatide Acetate as Treatment for Osteoporosis
Tokyo, Japan, September 5, 2022 --- Teijin Pharma Limited, the core company of theTeijin Group’s healthcare business, announced today that on August 31 the company
obtained manufacturing and sales approval from Japan’s Ministry of Health, Labour andWelfare for its abaloparatide acetate treatment OSTABALO® Subcutaneous Injection
Cart 1.5mg. The newly approved specification, which is for the treatment of osteoporosis,
is expected to help promote bone formation in patients with high risk of bone fractures.
OSTABALO ® Subcutaneous Injection Cart 1.5mg, which Teijin Pharma has positioned
as a strategic product for robust market penetration, is a new osteoplasty accelerator
that embodies the company’s extensive experience with treatments for bone and joint
diseases.
The active ingredient in OSTABALO® Subcutaneous Injection Cart 1.5mg isabaloparatide acetate, a polypeptide containing a modification of one part of the 34
amino acid sequences from the N-terminus of human parathyroid hormone-related
peptide. Abaloparatide acetate selectively stimulates RG-type parathyroid hormone type
1 receptors involved in bone metabolism. Abaloparatide acetate is subcutaneously
administered by aqueous injection (cartridge) once daily (80μg) for adults for up to 18months. With once-daily subcutaneous administration, it is expected to promote boneformation that exceeds bone resorption through an increase in bone mass, and toprevent bone fractures.
The efficacy and safety of abaloparatide acetate have been confirmed in clinical trials inJapan and worldwide involving osteoporosis patients with a high risk of bone fractures.
In April 2017, the U.S. Food and Drug Administration (FDA) granted approval to Radius
Health, Inc. for the use of abaloparatide acetate in treating osteoporosis in
postmenopausal women who are at high risk of fracture. For deployment in Japan, Teijin
Limited, the parent company of Teijin Pharma, signed a license agreement with Radiusin place for abaloparatide in July 2017 and the two companies have been partnering todevelop and gain approval in Japan for OSTABALO®.
According to a medical literature “2015 Guidelines for Prevention and Treatment ofOsteoporosis,” Japan is estimated to have about 13 million patients with osteoporosis,
many of whom are at risk of bone fractures that could greatly reduce their everyday
activity and quality of life. Osteoporosis is particularly troublesome for those with lowbone density, bone fragility or a high frequency of fractures due to aging. There is strong
demand in Japan for therapeutic drugs capable of increasing bone mass quickly to help
patients avoid debilitating bone fractures.

Teijin Pharma is helping to improve patients’ quality of life through solutions that address
problems with bones and joints, including through the company’s osteoporosis drugs
ONEALFA® and BONALON® (*) and sonic accelerated fracture healing system SAFHS®.
Teijin Pharma is committed to enhancing patients’ quality of life by providing newtreatment options for diseases with high unmet needs.
(*) BONALON® : Registered Trademark of NV Organon

About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company thatsupports the society of the future. The group comprises some 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2022
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp